Home Healthcare Healthcare Services Ophthalmic Clinical Trials Market

Ophthalmic Clinical Trials Market Size, Share & Trends Analysis Report By Phase (Discovery Phase, Preclinical Phase, Clinical Phase), By Therapeutic Modality (Drugs, Devices, Others), By Indication (Glaucoma, Macular Degeneration, Dry Eye Disease, Cataract & refractive, Uveitis, Retinopathy, Others), By Sponsor Type (Pharmaceutical & Biopharma Companies, Medical Device Companies, Others) and By Region (North America, Europe, APAC, Middle East and Africa, LATAM) Forecasts, 2026-2034

Last Updated: November 12, 2025 | Author: Debashree B | Format:
Overview TOC Segmentation Methodology
Download Free Sample

Market Segmentation

  1. Ophthalmic Clinical Trials Market, By Phase 2022-2034 (USD MILLION/ Units)
    1. Discovery Phase
    2. Preclinical Phase
    3. Clinical Phase
      1. Phase I
      2. Phase II
      3. Phase III
      4. Phase IV
  2. Ophthalmic Clinical Trials Market, By Therapeutic Modality 2022-2034 (USD MILLION/ Units)
    1. Drugs
      1. Small molecules
      2. Biologics
      3. Cell & Gene Therapies
    2. Devices
      1. Surgical & Diagnostics Devices
      2. Vision care Devices
    3. Others
  3. Ophthalmic Clinical Trials Market, By Indication 2022-2034 (USD MILLION/ Units)
    1. Glaucoma
    2. Macular Degeneration
    3. Dry Eye Disease
    4. Cataract & refractive
    5. Uveitis
    6. Retinopathy
    7. Others
  4. Ophthalmic Clinical Trials Market, By Sponsor Type 2022-2034 (USD MILLION/ Units)
    1. Pharmaceutical & Biopharma Companies
    2. Medical Device Companies
    3. Others
  5. Regional Ophthalmic Clinical Trials Market
    1. North America
      1. North America Ophthalmic Clinical Trials Market By Phase 2022-2034 (USD MILLION/ Units)
        1. Discovery Phase
        2. Preclinical Phase
        3. Clinical Phase
          1. Phase I
          2. Phase II
          3. Phase III
          4. Phase IV
      2. North America Ophthalmic Clinical Trials Market By Therapeutic Modality 2022-2034 (USD MILLION/ Units)
        1. Drugs
          1. Small molecules
          2. Biologics
          3. Cell & Gene Therapies
        2. Devices
          1. Surgical & Diagnostics Devices
          2. Vision care Devices
        3. Others
      3. North America Ophthalmic Clinical Trials Market By Indication 2022-2034 (USD MILLION/ Units)
        1. Glaucoma
        2. Macular Degeneration
        3. Dry Eye Disease
        4. Cataract & refractive
        5. Uveitis
        6. Retinopathy
        7. Others
      4. North America Ophthalmic Clinical Trials Market By Sponsor Type 2022-2034 (USD MILLION/ Units)
        1. Pharmaceutical & Biopharma Companies
        2. Medical Device Companies
        3. Others
      5. U.S.
        1. Discovery Phase
        2. Preclinical Phase
        3. Clinical Phase
          1. Phase I
          2. Phase II
          3. Phase III
          4. Phase IV
        4. Drugs
          1. Small molecules
          2. Biologics
          3. Cell & Gene Therapies
        5. Devices
          1. Surgical & Diagnostics Devices
          2. Vision care Devices
        6. Others
        7. Glaucoma
        8. Macular Degeneration
        9. Dry Eye Disease
        10. Cataract & refractive
        11. Uveitis
        12. Retinopathy
        13. Others
        14. Pharmaceutical & Biopharma Companies
        15. Medical Device Companies
        16. Others
      6. Canada
        1. Discovery Phase
        2. Preclinical Phase
        3. Clinical Phase
          1. Phase I
          2. Phase II
          3. Phase III
          4. Phase IV
        4. Drugs
          1. Small molecules
          2. Biologics
          3. Cell & Gene Therapies
        5. Devices
          1. Surgical & Diagnostics Devices
          2. Vision care Devices
        6. Others
        7. Glaucoma
        8. Macular Degeneration
        9. Dry Eye Disease
        10. Cataract & refractive
        11. Uveitis
        12. Retinopathy
        13. Others
        14. Pharmaceutical & Biopharma Companies
        15. Medical Device Companies
        16. Others
    2. Europe
      1. Europe Ophthalmic Clinical Trials Market By Phase 2022-2034 (USD MILLION/ Units)
        1. Discovery Phase
        2. Preclinical Phase
        3. Clinical Phase
          1. Phase I
          2. Phase II
          3. Phase III
          4. Phase IV
      2. Europe Ophthalmic Clinical Trials Market By Therapeutic Modality 2022-2034 (USD MILLION/ Units)
        1. Drugs
          1. Small molecules
          2. Biologics
          3. Cell & Gene Therapies
        2. Devices
          1. Surgical & Diagnostics Devices
          2. Vision care Devices
        3. Others
      3. Europe Ophthalmic Clinical Trials Market By Indication 2022-2034 (USD MILLION/ Units)
        1. Glaucoma
        2. Macular Degeneration
        3. Dry Eye Disease
        4. Cataract & refractive
        5. Uveitis
        6. Retinopathy
        7. Others
      4. Europe Ophthalmic Clinical Trials Market By Sponsor Type 2022-2034 (USD MILLION/ Units)
        1. Pharmaceutical & Biopharma Companies
        2. Medical Device Companies
        3. Others
      5. U.K.
        1. Discovery Phase
        2. Preclinical Phase
        3. Clinical Phase
          1. Phase I
          2. Phase II
          3. Phase III
          4. Phase IV
        4. Drugs
          1. Small molecules
          2. Biologics
          3. Cell & Gene Therapies
        5. Devices
          1. Surgical & Diagnostics Devices
          2. Vision care Devices
        6. Others
        7. Glaucoma
        8. Macular Degeneration
        9. Dry Eye Disease
        10. Cataract & refractive
        11. Uveitis
        12. Retinopathy
        13. Others
        14. Pharmaceutical & Biopharma Companies
        15. Medical Device Companies
        16. Others
      6. Germany
        1. Discovery Phase
        2. Preclinical Phase
        3. Clinical Phase
          1. Phase I
          2. Phase II
          3. Phase III
          4. Phase IV
        4. Drugs
          1. Small molecules
          2. Biologics
          3. Cell & Gene Therapies
        5. Devices
          1. Surgical & Diagnostics Devices
          2. Vision care Devices
        6. Others
        7. Glaucoma
        8. Macular Degeneration
        9. Dry Eye Disease
        10. Cataract & refractive
        11. Uveitis
        12. Retinopathy
        13. Others
        14. Pharmaceutical & Biopharma Companies
        15. Medical Device Companies
        16. Others
      7. France
        1. Discovery Phase
        2. Preclinical Phase
        3. Clinical Phase
          1. Phase I
          2. Phase II
          3. Phase III
          4. Phase IV
        4. Drugs
          1. Small molecules
          2. Biologics
          3. Cell & Gene Therapies
        5. Devices
          1. Surgical & Diagnostics Devices
          2. Vision care Devices
        6. Others
        7. Glaucoma
        8. Macular Degeneration
        9. Dry Eye Disease
        10. Cataract & refractive
        11. Uveitis
        12. Retinopathy
        13. Others
        14. Pharmaceutical & Biopharma Companies
        15. Medical Device Companies
        16. Others
      8. Spain
        1. Discovery Phase
        2. Preclinical Phase
        3. Clinical Phase
          1. Phase I
          2. Phase II
          3. Phase III
          4. Phase IV
        4. Drugs
          1. Small molecules
          2. Biologics
          3. Cell & Gene Therapies
        5. Devices
          1. Surgical & Diagnostics Devices
          2. Vision care Devices
        6. Others
        7. Glaucoma
        8. Macular Degeneration
        9. Dry Eye Disease
        10. Cataract & refractive
        11. Uveitis
        12. Retinopathy
        13. Others
        14. Pharmaceutical & Biopharma Companies
        15. Medical Device Companies
        16. Others
      9. Italy
        1. Discovery Phase
        2. Preclinical Phase
        3. Clinical Phase
          1. Phase I
          2. Phase II
          3. Phase III
          4. Phase IV
        4. Drugs
          1. Small molecules
          2. Biologics
          3. Cell & Gene Therapies
        5. Devices
          1. Surgical & Diagnostics Devices
          2. Vision care Devices
        6. Others
        7. Glaucoma
        8. Macular Degeneration
        9. Dry Eye Disease
        10. Cataract & refractive
        11. Uveitis
        12. Retinopathy
        13. Others
        14. Pharmaceutical & Biopharma Companies
        15. Medical Device Companies
        16. Others
      10. Russia
        1. Discovery Phase
        2. Preclinical Phase
        3. Clinical Phase
          1. Phase I
          2. Phase II
          3. Phase III
          4. Phase IV
        4. Drugs
          1. Small molecules
          2. Biologics
          3. Cell & Gene Therapies
        5. Devices
          1. Surgical & Diagnostics Devices
          2. Vision care Devices
        6. Others
        7. Glaucoma
        8. Macular Degeneration
        9. Dry Eye Disease
        10. Cataract & refractive
        11. Uveitis
        12. Retinopathy
        13. Others
        14. Pharmaceutical & Biopharma Companies
        15. Medical Device Companies
        16. Others
      11. Nordic
        1. Discovery Phase
        2. Preclinical Phase
        3. Clinical Phase
          1. Phase I
          2. Phase II
          3. Phase III
          4. Phase IV
        4. Drugs
          1. Small molecules
          2. Biologics
          3. Cell & Gene Therapies
        5. Devices
          1. Surgical & Diagnostics Devices
          2. Vision care Devices
        6. Others
        7. Glaucoma
        8. Macular Degeneration
        9. Dry Eye Disease
        10. Cataract & refractive
        11. Uveitis
        12. Retinopathy
        13. Others
        14. Pharmaceutical & Biopharma Companies
        15. Medical Device Companies
        16. Others
      12. Benelux
        1. Discovery Phase
        2. Preclinical Phase
        3. Clinical Phase
          1. Phase I
          2. Phase II
          3. Phase III
          4. Phase IV
        4. Drugs
          1. Small molecules
          2. Biologics
          3. Cell & Gene Therapies
        5. Devices
          1. Surgical & Diagnostics Devices
          2. Vision care Devices
        6. Others
        7. Glaucoma
        8. Macular Degeneration
        9. Dry Eye Disease
        10. Cataract & refractive
        11. Uveitis
        12. Retinopathy
        13. Others
        14. Pharmaceutical & Biopharma Companies
        15. Medical Device Companies
        16. Others
      13. Rest of Europe
        1. Discovery Phase
        2. Preclinical Phase
        3. Clinical Phase
          1. Phase I
          2. Phase II
          3. Phase III
          4. Phase IV
        4. Drugs
          1. Small molecules
          2. Biologics
          3. Cell & Gene Therapies
        5. Devices
          1. Surgical & Diagnostics Devices
          2. Vision care Devices
        6. Others
        7. Glaucoma
        8. Macular Degeneration
        9. Dry Eye Disease
        10. Cataract & refractive
        11. Uveitis
        12. Retinopathy
        13. Others
        14. Pharmaceutical & Biopharma Companies
        15. Medical Device Companies
        16. Others
    3. APAC
      1. APAC Ophthalmic Clinical Trials Market By Phase 2022-2034 (USD MILLION/ Units)
        1. Discovery Phase
        2. Preclinical Phase
        3. Clinical Phase
          1. Phase I
          2. Phase II
          3. Phase III
          4. Phase IV
      2. APAC Ophthalmic Clinical Trials Market By Therapeutic Modality 2022-2034 (USD MILLION/ Units)
        1. Drugs
          1. Small molecules
          2. Biologics
          3. Cell & Gene Therapies
        2. Devices
          1. Surgical & Diagnostics Devices
          2. Vision care Devices
        3. Others
      3. APAC Ophthalmic Clinical Trials Market By Indication 2022-2034 (USD MILLION/ Units)
        1. Glaucoma
        2. Macular Degeneration
        3. Dry Eye Disease
        4. Cataract & refractive
        5. Uveitis
        6. Retinopathy
        7. Others
      4. APAC Ophthalmic Clinical Trials Market By Sponsor Type 2022-2034 (USD MILLION/ Units)
        1. Pharmaceutical & Biopharma Companies
        2. Medical Device Companies
        3. Others
      5. China
        1. Discovery Phase
        2. Preclinical Phase
        3. Clinical Phase
          1. Phase I
          2. Phase II
          3. Phase III
          4. Phase IV
        4. Drugs
          1. Small molecules
          2. Biologics
          3. Cell & Gene Therapies
        5. Devices
          1. Surgical & Diagnostics Devices
          2. Vision care Devices
        6. Others
        7. Glaucoma
        8. Macular Degeneration
        9. Dry Eye Disease
        10. Cataract & refractive
        11. Uveitis
        12. Retinopathy
        13. Others
        14. Pharmaceutical & Biopharma Companies
        15. Medical Device Companies
        16. Others
      6. Korea
        1. Discovery Phase
        2. Preclinical Phase
        3. Clinical Phase
          1. Phase I
          2. Phase II
          3. Phase III
          4. Phase IV
        4. Drugs
          1. Small molecules
          2. Biologics
          3. Cell & Gene Therapies
        5. Devices
          1. Surgical & Diagnostics Devices
          2. Vision care Devices
        6. Others
        7. Glaucoma
        8. Macular Degeneration
        9. Dry Eye Disease
        10. Cataract & refractive
        11. Uveitis
        12. Retinopathy
        13. Others
        14. Pharmaceutical & Biopharma Companies
        15. Medical Device Companies
        16. Others
      7. Japan
        1. Discovery Phase
        2. Preclinical Phase
        3. Clinical Phase
          1. Phase I
          2. Phase II
          3. Phase III
          4. Phase IV
        4. Drugs
          1. Small molecules
          2. Biologics
          3. Cell & Gene Therapies
        5. Devices
          1. Surgical & Diagnostics Devices
          2. Vision care Devices
        6. Others
        7. Glaucoma
        8. Macular Degeneration
        9. Dry Eye Disease
        10. Cataract & refractive
        11. Uveitis
        12. Retinopathy
        13. Others
        14. Pharmaceutical & Biopharma Companies
        15. Medical Device Companies
        16. Others
      8. India
        1. Discovery Phase
        2. Preclinical Phase
        3. Clinical Phase
          1. Phase I
          2. Phase II
          3. Phase III
          4. Phase IV
        4. Drugs
          1. Small molecules
          2. Biologics
          3. Cell & Gene Therapies
        5. Devices
          1. Surgical & Diagnostics Devices
          2. Vision care Devices
        6. Others
        7. Glaucoma
        8. Macular Degeneration
        9. Dry Eye Disease
        10. Cataract & refractive
        11. Uveitis
        12. Retinopathy
        13. Others
        14. Pharmaceutical & Biopharma Companies
        15. Medical Device Companies
        16. Others
      9. Australia
        1. Discovery Phase
        2. Preclinical Phase
        3. Clinical Phase
          1. Phase I
          2. Phase II
          3. Phase III
          4. Phase IV
        4. Drugs
          1. Small molecules
          2. Biologics
          3. Cell & Gene Therapies
        5. Devices
          1. Surgical & Diagnostics Devices
          2. Vision care Devices
        6. Others
        7. Glaucoma
        8. Macular Degeneration
        9. Dry Eye Disease
        10. Cataract & refractive
        11. Uveitis
        12. Retinopathy
        13. Others
        14. Pharmaceutical & Biopharma Companies
        15. Medical Device Companies
        16. Others
      10. Taiwan
        1. Discovery Phase
        2. Preclinical Phase
        3. Clinical Phase
          1. Phase I
          2. Phase II
          3. Phase III
          4. Phase IV
        4. Drugs
          1. Small molecules
          2. Biologics
          3. Cell & Gene Therapies
        5. Devices
          1. Surgical & Diagnostics Devices
          2. Vision care Devices
        6. Others
        7. Glaucoma
        8. Macular Degeneration
        9. Dry Eye Disease
        10. Cataract & refractive
        11. Uveitis
        12. Retinopathy
        13. Others
        14. Pharmaceutical & Biopharma Companies
        15. Medical Device Companies
        16. Others
      11. South East Asia
        1. Discovery Phase
        2. Preclinical Phase
        3. Clinical Phase
          1. Phase I
          2. Phase II
          3. Phase III
          4. Phase IV
        4. Drugs
          1. Small molecules
          2. Biologics
          3. Cell & Gene Therapies
        5. Devices
          1. Surgical & Diagnostics Devices
          2. Vision care Devices
        6. Others
        7. Glaucoma
        8. Macular Degeneration
        9. Dry Eye Disease
        10. Cataract & refractive
        11. Uveitis
        12. Retinopathy
        13. Others
        14. Pharmaceutical & Biopharma Companies
        15. Medical Device Companies
        16. Others
      12. Rest of Asia-Pacific
        1. Discovery Phase
        2. Preclinical Phase
        3. Clinical Phase
          1. Phase I
          2. Phase II
          3. Phase III
          4. Phase IV
        4. Drugs
          1. Small molecules
          2. Biologics
          3. Cell & Gene Therapies
        5. Devices
          1. Surgical & Diagnostics Devices
          2. Vision care Devices
        6. Others
        7. Glaucoma
        8. Macular Degeneration
        9. Dry Eye Disease
        10. Cataract & refractive
        11. Uveitis
        12. Retinopathy
        13. Others
        14. Pharmaceutical & Biopharma Companies
        15. Medical Device Companies
        16. Others
    4. Middle East and Africa
      1. Middle East and Africa Ophthalmic Clinical Trials Market By Phase 2022-2034 (USD MILLION/ Units)
        1. Discovery Phase
        2. Preclinical Phase
        3. Clinical Phase
          1. Phase I
          2. Phase II
          3. Phase III
          4. Phase IV
      2. Middle East and Africa Ophthalmic Clinical Trials Market By Therapeutic Modality 2022-2034 (USD MILLION/ Units)
        1. Drugs
          1. Small molecules
          2. Biologics
          3. Cell & Gene Therapies
        2. Devices
          1. Surgical & Diagnostics Devices
          2. Vision care Devices
        3. Others
      3. Middle East and Africa Ophthalmic Clinical Trials Market By Indication 2022-2034 (USD MILLION/ Units)
        1. Glaucoma
        2. Macular Degeneration
        3. Dry Eye Disease
        4. Cataract & refractive
        5. Uveitis
        6. Retinopathy
        7. Others
      4. Middle East and Africa Ophthalmic Clinical Trials Market By Sponsor Type 2022-2034 (USD MILLION/ Units)
        1. Pharmaceutical & Biopharma Companies
        2. Medical Device Companies
        3. Others
      5. UAE
        1. Discovery Phase
        2. Preclinical Phase
        3. Clinical Phase
          1. Phase I
          2. Phase II
          3. Phase III
          4. Phase IV
        4. Drugs
          1. Small molecules
          2. Biologics
          3. Cell & Gene Therapies
        5. Devices
          1. Surgical & Diagnostics Devices
          2. Vision care Devices
        6. Others
        7. Glaucoma
        8. Macular Degeneration
        9. Dry Eye Disease
        10. Cataract & refractive
        11. Uveitis
        12. Retinopathy
        13. Others
        14. Pharmaceutical & Biopharma Companies
        15. Medical Device Companies
        16. Others
      6. Turkey
        1. Discovery Phase
        2. Preclinical Phase
        3. Clinical Phase
          1. Phase I
          2. Phase II
          3. Phase III
          4. Phase IV
        4. Drugs
          1. Small molecules
          2. Biologics
          3. Cell & Gene Therapies
        5. Devices
          1. Surgical & Diagnostics Devices
          2. Vision care Devices
        6. Others
        7. Glaucoma
        8. Macular Degeneration
        9. Dry Eye Disease
        10. Cataract & refractive
        11. Uveitis
        12. Retinopathy
        13. Others
        14. Pharmaceutical & Biopharma Companies
        15. Medical Device Companies
        16. Others
      7. Saudi Arabia
        1. Discovery Phase
        2. Preclinical Phase
        3. Clinical Phase
          1. Phase I
          2. Phase II
          3. Phase III
          4. Phase IV
        4. Drugs
          1. Small molecules
          2. Biologics
          3. Cell & Gene Therapies
        5. Devices
          1. Surgical & Diagnostics Devices
          2. Vision care Devices
        6. Others
        7. Glaucoma
        8. Macular Degeneration
        9. Dry Eye Disease
        10. Cataract & refractive
        11. Uveitis
        12. Retinopathy
        13. Others
        14. Pharmaceutical & Biopharma Companies
        15. Medical Device Companies
        16. Others
      8. South Africa
        1. Discovery Phase
        2. Preclinical Phase
        3. Clinical Phase
          1. Phase I
          2. Phase II
          3. Phase III
          4. Phase IV
        4. Drugs
          1. Small molecules
          2. Biologics
          3. Cell & Gene Therapies
        5. Devices
          1. Surgical & Diagnostics Devices
          2. Vision care Devices
        6. Others
        7. Glaucoma
        8. Macular Degeneration
        9. Dry Eye Disease
        10. Cataract & refractive
        11. Uveitis
        12. Retinopathy
        13. Others
        14. Pharmaceutical & Biopharma Companies
        15. Medical Device Companies
        16. Others
      9. Egypt
        1. Discovery Phase
        2. Preclinical Phase
        3. Clinical Phase
          1. Phase I
          2. Phase II
          3. Phase III
          4. Phase IV
        4. Drugs
          1. Small molecules
          2. Biologics
          3. Cell & Gene Therapies
        5. Devices
          1. Surgical & Diagnostics Devices
          2. Vision care Devices
        6. Others
        7. Glaucoma
        8. Macular Degeneration
        9. Dry Eye Disease
        10. Cataract & refractive
        11. Uveitis
        12. Retinopathy
        13. Others
        14. Pharmaceutical & Biopharma Companies
        15. Medical Device Companies
        16. Others
      10. Nigeria
        1. Discovery Phase
        2. Preclinical Phase
        3. Clinical Phase
          1. Phase I
          2. Phase II
          3. Phase III
          4. Phase IV
        4. Drugs
          1. Small molecules
          2. Biologics
          3. Cell & Gene Therapies
        5. Devices
          1. Surgical & Diagnostics Devices
          2. Vision care Devices
        6. Others
        7. Glaucoma
        8. Macular Degeneration
        9. Dry Eye Disease
        10. Cataract & refractive
        11. Uveitis
        12. Retinopathy
        13. Others
        14. Pharmaceutical & Biopharma Companies
        15. Medical Device Companies
        16. Others
      11. Rest of MEA
        1. Discovery Phase
        2. Preclinical Phase
        3. Clinical Phase
          1. Phase I
          2. Phase II
          3. Phase III
          4. Phase IV
        4. Drugs
          1. Small molecules
          2. Biologics
          3. Cell & Gene Therapies
        5. Devices
          1. Surgical & Diagnostics Devices
          2. Vision care Devices
        6. Others
        7. Glaucoma
        8. Macular Degeneration
        9. Dry Eye Disease
        10. Cataract & refractive
        11. Uveitis
        12. Retinopathy
        13. Others
        14. Pharmaceutical & Biopharma Companies
        15. Medical Device Companies
        16. Others
    5. LATAM
      1. LATAM Ophthalmic Clinical Trials Market By Phase 2022-2034 (USD MILLION/ Units)
        1. Discovery Phase
        2. Preclinical Phase
        3. Clinical Phase
          1. Phase I
          2. Phase II
          3. Phase III
          4. Phase IV
      2. LATAM Ophthalmic Clinical Trials Market By Therapeutic Modality 2022-2034 (USD MILLION/ Units)
        1. Drugs
          1. Small molecules
          2. Biologics
          3. Cell & Gene Therapies
        2. Devices
          1. Surgical & Diagnostics Devices
          2. Vision care Devices
        3. Others
      3. LATAM Ophthalmic Clinical Trials Market By Indication 2022-2034 (USD MILLION/ Units)
        1. Glaucoma
        2. Macular Degeneration
        3. Dry Eye Disease
        4. Cataract & refractive
        5. Uveitis
        6. Retinopathy
        7. Others
      4. LATAM Ophthalmic Clinical Trials Market By Sponsor Type 2022-2034 (USD MILLION/ Units)
        1. Pharmaceutical & Biopharma Companies
        2. Medical Device Companies
        3. Others
      5. Brazil
        1. Discovery Phase
        2. Preclinical Phase
        3. Clinical Phase
          1. Phase I
          2. Phase II
          3. Phase III
          4. Phase IV
        4. Drugs
          1. Small molecules
          2. Biologics
          3. Cell & Gene Therapies
        5. Devices
          1. Surgical & Diagnostics Devices
          2. Vision care Devices
        6. Others
        7. Glaucoma
        8. Macular Degeneration
        9. Dry Eye Disease
        10. Cataract & refractive
        11. Uveitis
        12. Retinopathy
        13. Others
        14. Pharmaceutical & Biopharma Companies
        15. Medical Device Companies
        16. Others
      6. Mexico
        1. Discovery Phase
        2. Preclinical Phase
        3. Clinical Phase
          1. Phase I
          2. Phase II
          3. Phase III
          4. Phase IV
        4. Drugs
          1. Small molecules
          2. Biologics
          3. Cell & Gene Therapies
        5. Devices
          1. Surgical & Diagnostics Devices
          2. Vision care Devices
        6. Others
        7. Glaucoma
        8. Macular Degeneration
        9. Dry Eye Disease
        10. Cataract & refractive
        11. Uveitis
        12. Retinopathy
        13. Others
        14. Pharmaceutical & Biopharma Companies
        15. Medical Device Companies
        16. Others
      7. Argentina
        1. Discovery Phase
        2. Preclinical Phase
        3. Clinical Phase
          1. Phase I
          2. Phase II
          3. Phase III
          4. Phase IV
        4. Drugs
          1. Small molecules
          2. Biologics
          3. Cell & Gene Therapies
        5. Devices
          1. Surgical & Diagnostics Devices
          2. Vision care Devices
        6. Others
        7. Glaucoma
        8. Macular Degeneration
        9. Dry Eye Disease
        10. Cataract & refractive
        11. Uveitis
        12. Retinopathy
        13. Others
        14. Pharmaceutical & Biopharma Companies
        15. Medical Device Companies
        16. Others
      8. Chile
        1. Discovery Phase
        2. Preclinical Phase
        3. Clinical Phase
          1. Phase I
          2. Phase II
          3. Phase III
          4. Phase IV
        4. Drugs
          1. Small molecules
          2. Biologics
          3. Cell & Gene Therapies
        5. Devices
          1. Surgical & Diagnostics Devices
          2. Vision care Devices
        6. Others
        7. Glaucoma
        8. Macular Degeneration
        9. Dry Eye Disease
        10. Cataract & refractive
        11. Uveitis
        12. Retinopathy
        13. Others
        14. Pharmaceutical & Biopharma Companies
        15. Medical Device Companies
        16. Others
      9. Colombia
        1. Discovery Phase
        2. Preclinical Phase
        3. Clinical Phase
          1. Phase I
          2. Phase II
          3. Phase III
          4. Phase IV
        4. Drugs
          1. Small molecules
          2. Biologics
          3. Cell & Gene Therapies
        5. Devices
          1. Surgical & Diagnostics Devices
          2. Vision care Devices
        6. Others
        7. Glaucoma
        8. Macular Degeneration
        9. Dry Eye Disease
        10. Cataract & refractive
        11. Uveitis
        12. Retinopathy
        13. Others
        14. Pharmaceutical & Biopharma Companies
        15. Medical Device Companies
        16. Others
      10. Rest of LATAM
        1. Discovery Phase
        2. Preclinical Phase
        3. Clinical Phase
          1. Phase I
          2. Phase II
          3. Phase III
          4. Phase IV
        4. Drugs
          1. Small molecules
          2. Biologics
          3. Cell & Gene Therapies
        5. Devices
          1. Surgical & Diagnostics Devices
          2. Vision care Devices
        6. Others
        7. Glaucoma
        8. Macular Degeneration
        9. Dry Eye Disease
        10. Cataract & refractive
        11. Uveitis
        12. Retinopathy
        13. Others
        14. Pharmaceutical & Biopharma Companies
        15. Medical Device Companies
        16. Others
Report Details
−
200+ Trusted Partners
LG Electronics AMCAD Engineering KOBE STEEL LTD. Hindustan National Glass & Industries Limited Voith Group International Paper Hansol Paper Whirlpool Corporation Sony Samsung Electronics Qualcomm Google Fiserv Veto-Pharma Nippon Becton Dickinson Merck Argon Medical Devices Abbott Ajinomoto Denon Doosan Meiji Seika Kaisha Ltd LG Chemicals LCY chemical group Bayer Airrane BASF Toyota Industries Nissan Motors Neenah Mitsubishi Hyundai Motor Company Honda CRP Industries Inc pewag LGE Panasonic Lubrizol Corporation Leonardo Johnson & Johnson HB Fuller MITSUBISHI CHEMICAL Hyundai Mobis Amazon
Download Free Sample
Reach out to us
+1 646 905 0080 (U.S.)
+44 203 695 0070 (U.K.)
sales@straitsresearch.com

We are featured on:

Straits Research
Address:
105, Panchshil The Golden Bell,
Koregaon Park Annexe, Mundhwa,
Pune, Maharashtra 411036
Contact Us:
+1 646 905 0080 (U.S.)
+91 8087085354 (India)
+44 203 695 0070 (U.K.)

sales@straitsresearch.com

Quick Links
Help
Verified. Protected. Secure.
Duns
DMCA.com Protection Status
lets-encrypt
Secure Payments:
Secure Payments
Follow Us:
www.straitsresearch.com © Copyright . All rights Reserved.